Skip to main content

07-19-2018 | Semaglutide | Article

A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin

Lingvay I et al. Diabetes Care 2018: dc172381. doi: 10.2337/dc17-2381

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

Related topics